Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary

Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalid...

Full description

Bibliographic Details
Main Authors: Szilvia Lovas, Nóra Obajed Al-Ali, Gergely Varga, Virág Szita, Hussain Alizadeh, Márk Plander, Péter Rajnics, Árpád Illés, Zsuzsa Szemlaky, Gábor Mikala, László Váróczy
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Pathology and Oncology Research
Subjects:
survival
toxicity
multiple myeloma
treatment response
pomalidomide
Online Access:https://www.por-journal.com/articles/10.3389/pore.2022.1610645/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2022.1610645/full

Similar Items